Gastropraxis Magdeburg

Research at Gastropraxis Magdeburg targets inflammatory bowel conditions, especially ulcerative colitis, aiming to improve remission rates and endoscopic healing.

• Oral controlled‑ileocolonic‑release nicotinamide therapy
• Top‑down biologic treatment with mirikizumab
• Assessment of disease activity through endoscopic and histologic endpoints

Gastropraxis Magdeburg is advancing therapeutic options for patients with mild to moderate disease, seeking faster symptom relief.

The center investigates immune‑modulating strategies for Crohn’s disease and ulcerative colitis, reflecting the immune basis of these disorders.

• Comparative efficacy of mirikizumab versus azathioprine
• Long‑term remission and comprehensive disease control
• Pharmacokinetic study of mirikizumab in lactating individuals

Through these studies, Gastropraxis Magdeburg contributes to understanding how targeted biologics can reshape treatment paradigms for immune‑mediated gut diseases.